Clinical Research in Multiple Myeloma: Recent literature – Editors’ picks

Compiled by Efstathios Kastritis, MD
National and Kapodistrian University of Athens


Newly diagnosed MM – Transplant eligible

Newly diagnosed transplant ineligible

Relapsed Myeloma

Immunotherapy and cellular therapy for myeloma

Minimal Residual Disease

Prognosis – Genetics

  •  The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, Asmann YW, Peterson JF, Ketterling RP, Greipp PT, Bergsagel PL, Rajkumar SV, Kumar SK, Baughn LB.Clin Cancer Res. 2021 Jul 7. doi: 10.1158/1078-0432.CCR-21-0005. Online ahead of print.PMID: 34233962
  • Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma. Haertle L, Barrio S, Munawar U, Han S, Zhou X, Vogt C, Alonso R, Bittrich M, Ruiz-Heredia Y, Da-Via M, Zovko J, Garitano-Trojaola A, Bolli N, Ruckdeschel A, Stühmer T, Chatterjee M, Kull M, Krönke J, Agirre X, Martin-Subero I, Raab P, Einsele H, Rasche L, Martinez-Lopez J, Haaf T, Kortüm KM.Blood. 2021 Jun 11:blood.2020010452. doi: 10.1182/blood.2020010452. Online ahead of print.PMID: 3411583

AL Amyloidosis

  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators.N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.PMID: 34192431 Clinical Trial.
  • A randomized phase 3 study of ixazomib-dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G.Leukemia. 2021 Jun 24. doi: 10.1038/s41375-021-01317-y. Online ahead of print.PMID: 34168284

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events